{"disease":{"id":"gastrointestinal-stromal-tumour","name":"gastrointestinal stromal tumour"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07124000","title":"DESTINY-PANTUMOUR04","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02365441","title":"A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Australasian Gastro-Intestinal Trials Group","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}